{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:11:04Z","timestamp":1793315464991,"version":"4.5.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chronic myeloid leukemia (CML), characterized by the presence of the <jats:italic>BCR::ABL1<\/jats:italic> fusion gene, has undergone a transformative shift with the introduction of tyrosine kinase inhibitors (TKIs). The current availability of six different TKIs (imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib) in clinical practice makes it important to know their efficacy and toxicity profile for treatment optimization. This review examines the latest insights regarding the use of bosutinib in CML treatment. Clinical trials have demonstrated the effectiveness of bosutinib, positioning it as a first-line treatment that can induce sustained molecular responses. Importantly, it can also be effective in patients who have experienced treatment failure or intolerance with prior TKIs, revealing the potential of bosutinib also in second- and later-line settings. Even in the advanced phase of CML, bosutinib has demonstrated its capacity to achieve molecular responses, expanding its usefulness. Real-world evidence studies echo these findings, emphasizing bosutinib\u2019s effectiveness in achieving deep molecular responses, maintaining remissions, and serving as an alternative for patients intolerant or resistant to other TKIs as a second-line therapy. Notably, one of the greatest strengths of bosutinib is its favorable safety profile, in particular the low incidence of vascular complications with its use, which is undoubtedly a comparative advantage over other TKIs. In summary, the latest research highlights the versatility of bosutinib in CML treatment and underscores its pivotal role in optimizing patient management in challenging cases. Continuing research and investigation will further establish bosutinib\u2019s place in the evolving landscape of CML therapy, offering an alternative for CML patients across different treatment stages.<\/jats:p>","DOI":"10.3389\/fonc.2024.1405467","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T04:54:17Z","timestamp":1724648057000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia"],"prefix":"10.3389","volume":"14","author":[{"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"G\u00f3mez-Casares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Casado-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Orti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30232-6","article-title":"Epidemiological patterns of leukaemia in 184 countries: a population-based study","volume":"5","author":"Miranda-Filho","year":"2018","journal-title":"Lancet Haematology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S382090","article-title":"Chronic myeloid leukemia, from pathophysiology to treatment-free remission: A narrative literature review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J Blood Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2196866","DOI":"10.1080\/16078454.2023.2196866","article-title":"Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies","volume":"28","author":"Younes","year":"2023","journal-title":"Hematology"},{"key":"B4","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000329","article-title":"Transplantation in CML in the TKI era: who, when, and how","volume":"2022","author":"Niederwieser","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/OTT","article-title":"Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia","author":"Koschmieder","year":"2013","journal-title":"OncoTargets Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"iv261","DOI":"10.1093\/annonc\/mdy159","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Hochhaus","year":"2018","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"key":"B16","volume-title":"Summary of product characteristics","year":""},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0391-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of bosutinib","volume":"55","author":"Abbas","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1688-7","article-title":"A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects","volume":"69","author":"Abbas","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"B19","volume-title":"Bosulif (bosutinib) prescribing information","year":"2017"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7002","article-title":"Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Brummendorf","year":"2022","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03435-4","article-title":"Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study","volume":"116","author":"Ono","year":"2022","journal-title":"Int J Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1896489","article-title":"An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia","volume":"37","author":"Muresan","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23728","article-title":"Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171249","article-title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I\/II study","volume":"103","author":"Gambacorti-Passerini","year":"2018","journal-title":"Haematologica"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0915-9","article-title":"Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1182\/blood-2021-150352","article-title":"Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the byond trial","volume":"138","author":"Gambacorti-Passerini","year":"2021","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1605239","article-title":"Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia","volume":"35","author":"Cortes","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120","article-title":"Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure","volume":"119","author":"Khoury","year":"2012","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-3-319-91439-8_4","article-title":"Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor. Recent results in cancer research. Fortschritte der Krebsforschung","volume":"212","author":"Isfort","year":"2018","journal-title":"Progres dans les recherches sur le Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24034","article-title":"Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors","volume":"90","author":"Gambacorti-Passerini","year":"2015","journal-title":"Am J Hematol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Brummendorf","year":"2015","journal-title":"Br J Haematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26238","article-title":"Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia","volume":"96","author":"Jain","year":"2021","journal-title":"Am J Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113427","article-title":"Real life evaluation of efficacy and safety of bosutinib therapy in chronic myeloid leukemia patients","volume":"132","author":"Costa","year":"2018","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13775","article-title":"A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands","volume":"109","author":"Claudiani","year":"2022","journal-title":"Eur J Haematol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1182\/blood.V128.22.5435.5435","article-title":"The real world use of bosutinib in patients with chronic myeloid leukaemia","volume":"128","author":"Apperley","year":"2016","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3507-2","article-title":"Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients","volume":"98","author":"Garcia-Gutierrez","year":"2019","journal-title":"Ann Hematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7039","article-title":"Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib","volume":"39","author":"Deininger","year":"2021","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6439","article-title":"Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia","volume":"12","author":"Garrett","year":"2023","journal-title":"Cancer Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05394-0","article-title":"Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study","volume":"102","author":"Isfort","year":"2023","journal-title":"Ann Hematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000845676.81208.c2","article-title":"P698: Bosutinib dose optimization in the second-line treatment of elderly cml patients: extended 3-year follow-up and final results of the best study","volume":"6","author":"Castagnetti","year":"2022","journal-title":"HemaSphere"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy019","article-title":"Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"29","author":"Khoury","year":"2018","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bjh.13801","article-title":"Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib","volume":"172","author":"Br\u00fcmmendorf","year":"2016","journal-title":"Br J Haematology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B55","article-title":"POSTER PC-353-Simbi\u00f3tico conteniendo Bacillus Coagulans lmg-s-24828 y prebi\u00f3ticos en la reducci\u00f3n de trastornos gastrointestinales secundarios al tratamiento farmacol\u00f3gico de enfermedades hematol\u00f3gicas cr\u00f3nicas. Estudio piloto","volume-title":"LX Congreso Nacional de la Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","author":"Medrano-Engay","year":"2018"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13608","article-title":"Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy","volume":"106","author":"Cortes","year":"2021","journal-title":"Eur J Haematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01410-2016","article-title":"Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity","volume":"48","author":"Riou","year":"2016","journal-title":"Eur Respir J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03802-y","article-title":"Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy","volume":"98","author":"Tiribelli","year":"2019","journal-title":"Ann Hematol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.clml.2017.06.001","article-title":"Effects of bosutinib treatment on renal function in patients with philadelphia chromosome-positive leukemias","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B60","doi-asserted-by":"publisher","first-page":"IJH26","DOI":"10.2217\/ijh-2020-0004","article-title":"Pregnancy outcomes in patients treated with bosutinib","volume":"9","author":"Cortes","year":"2020","journal-title":"Int J Hematol Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"JCO2300897","DOI":"10.1200\/JCO.23.00897","article-title":"Bosutinib in resistant and intolerant pediatric patients with chronic phase chronic myeloid leukemia: results from the phase I part of study ITCC054\/COG AAML1921","author":"Brivio","year":"2023","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145709","article-title":"A phase I\/II study of bosutinib in pediatric patients with resistant\/intolerant or newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia, study ITCC (Innovative therapies for children with cancer european consortium) 054 and COG (Children\u2019s oncology group consortium) AAML1921: results from the phase I trial in resistant\/intolerant patients","volume":"138","author":"Pennesi","year":"2021","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"134","DOI":"10.15344\/2456-3501\/2018\/134","article-title":"Comparative pharmacology of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"3","author":"Azanza","year":"2018","journal-title":"Int J Clin Pharmacol Pharmacother"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117075","article-title":"Ponatinib and bosutinib discontinuation in chronic myeloid leukemia (CML): single center experience","volume":"132","author":"Alfayez","year":"2018","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1405467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T04:54:22Z","timestamp":1724648062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1405467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":65,"alternative-id":["10.3389\/fonc.2024.1405467"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1405467","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"article-number":"1405467"}}